Half of regressed polypoidal choroidal vasculopathy recurs within two years of stopping injections

The edition in brief

Four items for ophthalmologists. In 81 treatment-naive eyes with polypoidal choroidal vasculopathy given aflibercept, 40% achieved complete polypoidal regression; of 26 regressed eyes then treated as needed, half recurred within two years, and recurrences cost a median 3.5 letters, with 21% losing 10 or more and 36% developing new haemorrhage. In 305 eyes with culture-positive endogenous endophthalmitis at nine US centres, S. aureus was the commonest organism, blood cultures were positive in 66% but vitreous in only 31%, presenting acuity was the strongest predictor of final vision, and enucleation was highest with gram-negative infection (27.7%), especially Serratia. A meta-analysis of 466 patients with anti-TNF-refractory non-infectious uveitis found 83% responded after a biologic switch, with interclass switching favoured over intraclass (85% vs 71% in sensitivity analysis). The FDA recorded a supplement to Samsung Bioepis's ranibizumab biosimilar Byooviz. The pearl covers the systemic workup for endogenous endophthalmitis.